The Regenerative Medicine Group in Reliance Life Sciences is developing a wide range of novel research-led, autologous and allogeneic cell therapies and tissue engineered products, with the objective of bringing about an era of regenerative medicine by unlocking the potential of human pluripotent stem cells. Given the huge disease burden and the need for affordable diagnostics and therapies in India, the Group aims to come up with better and cost-effective ways to treat people with unmet medical needs.

Under the Regenerative Medicine initiative, several groups work in the areas of:

  • Embryonic Stem Cells
  • Adult Stem Cells
  • Cord blood banking
  • Stem cell expansion and banking

Cell-based therapies from Reliance Life Sciences aim to meet unmet patient needs in the areas of:
  • Cardiac Disorders
  • Neural Degeneration
  • Spinal Cord Injury
  • Metabolic Disorders
  • Ophthalmic Diseases
  • Treatment of chronic and non-healing ulcers
  • Diabetic and Venous Ulcers including chronic non-healing ulcers
  • Skin Pigmentation Disorders
  • Bone and Cartilage Disorders
The various stem cell-based activities undertaken by the Group is approved and monitored by an Institutional Committee for Stem Cell Research (IC-SCR), in accordance with the existing regulatory guidelines. Clinical trials of all cell-based therapies are conducted after receiving regulatory approval from Drug Controller General of India.

Reliance Life Sciences has established the safety and efficacy of the following therapies in clinical trials:

    1. ReliNethra® : Autologous composite limbal epithelial graft prepared from the limbal biopsy for treating corneal disorders.


    2. ReliNethra® C : Autologous conjunctival epithelial stem cell graft prepared from the excised conjunctival biopsy for treating conjunctival disorders.


    3. Autologous bone marrow derived mesenchymal stem cells for:


    4.     a.  Cardiac disorders (CardioRel®)
          b.  Neurological disorders (NeuroRel)


Services offered by the group:
  • Allogenic umbilical cord tissue derived mesenchymal stem cells


  • Relicord Superior (Relicord S): Banking of cord blood and cord tissue derived stem cells (1 million cells).

  • Relicord M50: Banking of cord blood and cord tissue derived stem cells (50 million cells).


  • Relicord A: Public banking donor program meant for general patients requiring grafts from the cord blood repository.

  • Relicord ST: Banking of cord blood and cord tissue.

  • Expanded CD34+cells: For patients requiring higher cell dose.
  • Processing of cells under cGMP conditions (Bone marrow derived mesenchymal stem cells, autologous myoblasts from skeletal muscle biopsies.)


Cells available for research:

  1. In-house derived Human Embryonic stem cell lines (Relicell®hES1, Relicell®hES2 and Relicell®hES3¬). These cell lines are registered with International Stem Cell Registry (UMASS, USA).


  2. Human umbilical cord tissue derived mesenchymal stem cells (UCMSCs)


  3. Human umbilical cord blood derived hematopoietic stem Cells (CD34+ cells)

Technical courses offered:

RLS offers cutting edge training courses on various aspects of cell culture techniques. Based on the competency requirement of the participants, the program is divided into two different modules.

  1. Module1: Basic Cell Culture Technique


  2. Module 2 (Advanced level): Human Embryonic Stem Cell Culture